Does an elevated PSA always mean prostate cancer?

No. Benign prostatic hyperplasia, prostatitis, recent ejaculation, and prostatic instrumentation all elevate PSA. Cancer probability rises with higher values, but the intermediate range (4–10 ng/mL) shows substantial overlap between benign and malignant causes, so free PSA ratio, imaging, and clinical context guide the next step.

Should patients avoid sexual activity before a PSA test?

Yes. Ejaculation within 48 hours can transiently raise PSA. Patients should abstain for at least two days before the blood draw to avoid a spurious elevation.

Can a digital rectal exam affect PSA results?

A gentle DRE causes minimal change, but vigorous examination or any prostatic instrumentation (biopsy, catheter, cystoscopy) can elevate PSA for days to weeks. Best practice is to draw blood before the examination or defer testing until PSA normalises.

How does finasteride or dutasteride affect PSA?

These 5α-reductase inhibitors shrink the prostate and lower PSA by approximately 50 per cent after six months of therapy. Practitioners should double the measured value when interpreting results in men on treatment.

What is PSA velocity and why does it matter?

PSA velocity is the rate of rise over time, typically expressed as ng/mL per year. A velocity above 0.75 ng/mL per year raises concern for malignancy even when absolute values remain within reference limits, so serial testing adds more information than a single result.

What PSA level indicates biochemical recurrence after prostatectomy?

After radical prostatectomy, PSA should become undetectable. Biochemical recurrence is defined as two consecutive values of 0.2 ng/mL or higher, prompting investigation for local or distant relapse.

Is fasting required for a PSA test?

No. PSA does not require fasting, and the test can be drawn at any time of day.

Can obesity affect PSA results?

Yes. Higher body mass index is associated with lower PSA concentrations through haemodilution and hormonal effects, which may mask early cancer. Some experts suggest using lower thresholds for further investigation in obese men.

BML-HRM-023male hormonesUSA

Prostate-Specific Antigen (PSA)

The PSA test measures serum prostate-specific antigen, a glycoprotein secreted by prostatic epithelium that rises with glandular disruption from cancer, benign hyperplasia, or inflammation. It is the cornerstone biomarker for prostate cancer screening in shared decision-making and for post-treatment surveillance, interpreted with age, trends, free-to-total ratio, and clinical context.

Biomarkers

Blood (serum)

Sample

1–2 business days

Turnaround

Fasting

What is the PSA test?

The Prostate-Specific Antigen test quantifies circulating PSA, a glycoprotein secreted by prostatic epithelium that leaks into serum when glandular architecture is disrupted. It is the most widely used blood biomarker in men's health, ordered both to screen asymptomatic men for prostate cancer and to monitor those already diagnosed or treated for the disease. PSA occupies a unique and sometimes contentious position in preventive medicine. Because it lacks perfect specificity—benign prostatic hyperplasia, prostatitis, and even ejaculation can raise it—and because not all prostate cancers detected are clinically significant, screening must be offered within a framework of informed, shared decision-making. Practitioners order PSA to identify men who may benefit from further investigation with imaging or biopsy, to track disease status after surgery or radiotherapy, and to detect biochemical recurrence years before clinical symptoms appear.

What does the PSA test measure?

PSA(Prostate-Specific Antigen, Total)

Range: Age-adjusted; typically <4.0 ng/mL in men under 50, with higher thresholds in older decades.Optimal: Optimal PSA thresholds are debated and individualised by age, race, family history, and shared decision-making around screening benefits and harms; many guidelines avoid a single 'optimal' cut-off in favour of risk stratification.ng/mL / µg/L

Prostate-specific antigen is a serine protease produced predominantly by epithelial cells of the prostate gland, where it liquefies seminal fluid. Small amounts normally enter the circulation, but disruption of the glandular architecture—whether by malignancy, benign hyperplasia, inflammation, or mechanical trauma—raises serum concentrations. PSA is not cancer-specific; any process that increases gland volume or damages epithelial integrity will elevate it.

PSA is the cornerstone blood biomarker for prostate cancer screening and post-treatment surveillance. Its strength lies in longitudinal trends and integration with free-to-total PSA ratio, clinical findings, and imaging rather than in a single threshold. Rising PSA velocity and persistently elevated values prompt further investigation, while stable low values offer reassurance. In survivors treated for prostate cancer, undetectable or stable PSA signals remission, whereas biochemical recurrence is defined by rising values.

Why is the PSA test ordered?

Shared decision-making screening in men aged 50–70 (or from 40–45 in those with African ancestry or a family history of prostate cancer) who have a life expectancy of at least 10 years
Investigation of lower urinary tract symptoms when prostate pathology is suspected, interpreted alongside digital rectal examination and symptom scores
Baseline and serial surveillance in men diagnosed with low-risk prostate cancer managed by active surveillance protocols
Post-treatment monitoring after radical prostatectomy, radiotherapy, or androgen-deprivation therapy to detect biochemical recurrence
Evaluation of persistently abnormal digital rectal examination findings, even when initial PSA is within reference limits
Risk stratification before prostate biopsy, often combined with free PSA or newer derivative biomarkers (PHI, 4Kscore) to refine selection
Follow-up of a previous elevated or rising PSA to confirm persistence and calculate velocity

Sample collection and turnaround

Sample type

Blood (serum)

Fasting required

Collection method

Venipuncture at patient service centre

Turnaround

1–2 business days

Collection notes

Phlebotomy at the LabCorp draw site; no fasting required. Patients should avoid ejaculation for 48 hours and vigorous cycling or prostatic trauma immediately before the draw. Blood must be collected before digital rectal examination or at least 48 hours afterward, and weeks after prostate biopsy or transurethral procedures.

Specimen requirements

Minimum 0.5 mL serum (gel separator acceptable). PSA is stable refrigerated for up to one week and frozen for months. Note the performing laboratory and assay platform for serial comparability, as methods differ slightly.

What can affect PSA results?

elevatesEjaculation within 24–48 hours

Sexual activity transiently raises serum PSA through normal prostatic secretion and minor trauma; patients should abstain for at least 48 hours before the draw.

elevatesDigital rectal examination and prostatic manipulation

Vigorous DRE, prostate biopsy, cystoscopy, or catheterisation can elevate PSA for days to weeks; blood should be drawn before the examination or deferred until PSA normalises.

elevatesBenign prostatic hyperplasia

BPH increases gland volume and disrupts architecture, commonly raising PSA into the intermediate range (4–10 ng/mL) without malignancy; free-to-total PSA ratio and clinical context help discriminate.

elevatesProstatitis and urinary tract infection

Acute or chronic prostatic inflammation markedly raises PSA; repeating the test after antibiotic treatment and resolution of symptoms is standard practice.

reduces5α-reductase inhibitors (finasteride, dutasteride)

These drugs shrink prostate volume and lower PSA by approximately 50 per cent after six months; practitioners should double the measured value when interpreting results in men on therapy.

reducesObesity

Higher body mass index is associated with lower PSA concentrations through haemodilution and hormonal effects, potentially masking early cancer; some experts advocate lowering thresholds in obese men.

What do PSA results mean?

Elevated

Prostate cancer, benign prostatic hyperplasia, acute or chronic prostatitis, and recent prostatic instrumentation or ejaculation. Very high values (>10–20 ng/mL) carry a higher probability of malignancy, but intermediate elevations (4–10 ng/mL) overlap substantially between benign and malignant disease. Reflex free PSA, imaging (multiparametric MRI), and clinical risk factors guide the decision to proceed to biopsy.

Normal

A PSA within age-specific reference limits offers reassurance but does not categorically exclude prostate cancer, especially high-grade disease that may not produce marked PSA elevation. Serial results and velocity over time add more information than a single normal value, and abnormal DRE findings warrant investigation regardless of PSA.

Reduced

Low PSA is the desired state. Pharmacological reduction with 5α-reductase inhibitors is intentional and expected; in that setting the measured value should be doubled for screening interpretation. Very low or undetectable PSA after radical prostatectomy signals complete tumour removal and no biochemical recurrence.

Note: PSA must be interpreted with the patient's age, prostate volume, family history, and the interval from prior manipulation or ejaculation. The decision to screen and the threshold for further investigation rest on shared decision-making. After treatment, 'biochemical recurrence' is defined by validated thresholds (≥0.2 ng/mL post-prostatectomy; rise ≥2 ng/mL above nadir post-radiotherapy) rather than the screening reference range.

Frequently asked questions

Reference limits rise with age because prostate volume increases. Commonly cited thresholds are below 2.5 ng/mL in men under 50, below 4.0 ng/mL in men 50–60, and up to 5.0–6.5 ng/mL in older decades, though these remain debated and individualised by risk factors.

How to access the PSA test

The PSA reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.

Create Free Account

About this page

Published: October 7, 2026

Last reviewed: October 7, 2026

References:

US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. (2018)
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer early detection. (2025)
European Association of Urology guidelines on prostate cancer. (2024)
Catalona WJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. (1991)
Cookson MS, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report. J Urol. (2007)

This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.

Related tests

male hormones

Total Testosterone

The total testosterone test measures the sum of free, albumin-bound, and SHBG-bound testosterone in serum. It is the first-line androgen assessment in males with suspected hypogonadism and in females with hyperandrogenism, requiring morning collection to account for diurnal variation and interpretation alongside SHBG, LH, and FSH to classify androgen disorders.

BML-HRM-006View reference →